Article
Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathway.
PLoS genetics - 1 May 2013
Li Gang, Diogo Dorothée, Wu Di, Spoonamore Jim, Dancik Vlado, Franke Lude, Kurreeman Fina, Rossin Elizabeth J, Duclos Grant, Hartland Cathy, Zhou Xuezhong, Li Kejie, Liu Jun, De Jager Philip L, Siminovitch Katherine A, Zhernakova Alexandra, Raychaudhuri Soumya, Bowes John, Eyre Steve, Padyukov Leonid, Gregersen Peter K, Worthington Jane, Gupta Namrata, Clemons Paul A, Stahl Eli, Tolliday Nicola, Plenge Robert M
Abstract excerpt
Although genetic and non-genetic studies in mouse and human implicate the CD40 pathway in rheumatoid arthritis (RA), there are no approved drugs that inhibit CD40 signaling for clinical care in RA or any other disease. Here, we sought to understand the biological consequences of a CD40 risk variant in RA discovered by a previous genome-wide association study (GWAS) and to perform a high-throughput drug screen for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.